• Application Note

Characterization of Biotherapeutics: ACQUITY UPLC H-Class Bio with 2D Part 2 of 3: Rendering a Viable Interface for IEX with ESI-MS Analysis

Characterization of Biotherapeutics: ACQUITY UPLC H-Class Bio with 2D Part 2 of 3: Rendering a Viable Interface for IEX with ESI-MS Analysis

  • Robert E. Birdsall
  • Sean M. McCarthy
  • Weibin Chen
  • Waters Corporation

Abstract

In the second part of this three-part series, we address how to successfully interface ion exchange chromatography (IEX) with ESI mass spectrometry as a complementary orthogonal technique to monitor lysine variants.

Benefits

  • Increased productivity through the automation of the fractionation processes using an ACQUITY UPLC H-Class Bio System with 2D Technology
  • Improved efficiency through on-line desalting of complex biological therapeutic samples
  • 2D UPLC is a viable option for interfacing IEX with ESI-MS

Introduction

Charge variants, such as C-terminal lysine variants in monoclonal antibodies, are known to be sensitive to manufacturing processes.1-3 Developing efficient methods for characterization and identification of charge variants in biotherapeutic proteins for monitoring and control of production processes is an area of continued interest in the pharmaceutical industry.

Orthogonal techniques such as ion exchange chromatography (IEX) and mass spectrometry (MS) are often employed to maximize the information gained in the characterization of biotherapeutics.4 While IEX separations are powerful in gathering information such as charge variant composition, the use of salts and buffer components prevents direct coupling to mass spectrometry (MS) to elucidate peak identity.5 Chromatographic fractions of interest are often manually collected, and desalted offline prior to MS analysis, which negatively impact overall analysis time and productivity.

Part 1 of this three-part application series demonstrated that the Waters ACQUITY UPLC H-Class Bio System with 2D Technology offers an efficient solution for increasing productivity in the fractionation and desalting of charge variants in complex biotherapeutic samples. When coupled to a mass spectrometer, the ACQUITY UPLC H-Class Bio System with 2D Technology renders an efficient method for combining complementary orthogonal techniques employed in the monitoring of C-terminal lysine variants in therapeutic monoclonal antibodies without compromising productivity.

The objective of this application note is to demonstrate that the ACQUITY UPLC H-Class Bio System with 2D Technology is a viable option for interfacing IEX to electrospray ionization (ESI)-MS. A therapeutic monoclonal antibody, infliximab, was used as a model protein to evaluate the functionality.

Experimental

The Waters Protein-Pak Hi Res SP, 7 μm, 4.6 x 100 mm, strong cation exchange column (p/n 186004930) and ACQUITY UPLC Protein BEH C4, 300Å, 1.7 μm, 2.1 x 50 mm Column (p/n 186004495) were conditioned prior to use. Chemical reagents were purchased from Sigma Aldrich and used as received. The monoclonal antibody infliximab was received at a concentration of 20 mg/mL.

LC conditions

LC system:

ACQUITY UPLC H-Class Bio with 2D Technology

1st dimension pump: ACQUITY UPLC Quaternary Solvent Manager, ACQUITY UPLC Column manager

2nd dimension pump: ACQUITY UPLC Binary Solvent Manager, ACQUITY UPLC Autosampler with FTN, ACQUITY UPL Column Manager

Detectors:

(1st dimension) ACQUITY UPLC TUV

(2nd dimension) ACQUITY UPLC PDA

Absorption wavelength:

280 nm

Vials:

Total recovery vial:12 x 32 mm glass, screw neck, cap, nonslit (p/n 600000750cv)

Column:

Protein-Pak Hi Res SP, 7 μm, 4.6 x 100 mm (p/n 186004930)

ACQUITY UPLC BEH C4, 300Å, 1.7 μm, 2.1 x 50 mm (p/n 186004495)

Column temp.:

25 °C (IEX); 80 °C (C4)

Sample temp.:

4 °C

Injection vol.:

2 μL unless otherwise stated

IEX/RPLC Pump Configuration

Quaternary solvent manager:

Flow rate:

0.500 mL/min

Mobile phase A:

100 mM MES monohydrate

Mobile phase B:

100 mM MES sodium salt

Mobile phase C:

1000 mM NaCl

Mobile phase D:

18 MΩ H2O

Auto•Blend Plus setting:

20 mM MES buffer, pH 6.5, 25–65 mM NaCl in 15 minutes

Binary solvent manager:

Flow rate:

0.250 mL/min for heart-cut, otherwise 0.500 mL/min

Mobile phase A:

18MΩ H2O, 0.1% FA

Mobile phase B:

Acetonitrile, 0.1% FA

Gradient:

5–85% B in 10 minutes

MS conditions

Capillary:

3kV

Sample cone:

45 V

Source temp.:

150 °C

Desolvation temp.:

500 °C

Desolvation gas:

800 L/h

Data Management

MassLynx Software v4.1 (SCN 8.62)

Results and Discussion

ACQUITY UPLCH-Class Bio System with 2D Technology featuring heart-cut technology

As described in part 1 of this three part series, the ACQUITY UPLC H-Class Bio System with 2D Technology featuring the heart-cut process is readily deployed with a two-column configuration as shown in Figure 1. With both valves in position 1 (Figure 1A), the flow from both the quaternary solvent manager and binary solvent manger are independent of each other, allowing for independent gradients to be performed on column 1 and 2.

Figure 1. A plumbing diagram of the ACQUITY UPLC H-Class Bio System with 2D Technology and corresponding valve positions to perform a heart-cut are illustrated in A–D. A) Three charge variants (peak 1–3) are separated in the 1st dimension (IEX) using the ACQUITY UPLC Quaternary Solvent Manager to deliver a salt gradient. B) Synchronized valve switching diverts the flow path to the 2nd dimension where a fraction (heart-cut) of peak 2 is directed to the 2nd dimension column (RPLC). C) Independent valve control allows the left valve to re-engage flow to the 1st dimension column while the right valve remains in position 2 where the heart-cut of peak 2 has unbound salt removed under aqueous conditions from the ACQUITY UPLC Binary Solvent Manager. D) The right valve is returned to position 1 after desalting the heart-cut fraction and a standard reversed phase gradient is used to elute the fraction for MS analysis.

The heart cut is performed when the valve positions are temporarily switched to position 2 (Figure 1B), combining the flow paths (Figure 1B blue trace) where eluent from column 1 is redirected to column 2. The ACQUITY UPLC Column Manager supports independent valve control as shown in Figure 2C. With the left valve in position 1 and the right valve in position 2 the flow paths of each column are isolated again, with the 2nd dimension column being eluted to waste. This allows for unbound salts to be washed from the heart-cut fraction, which is trapped at the column head of the 2nd dimension column, using the aqueous phase of the 2nd dimension.

Once desalted, the heart-cut fraction can be readily eluted in a mobile phase amendable to MS analysis using the ACQUITY UPLC Binary Solvent Manager, demonstrating the ACQUITY UPLC H-Class Bio System with 2D Technology facilitates a viable option for interfacing IEX to MS analysis.

Auto•Blend Plus for reproducible 1st dimension separations

One aspect of successful multidimensional chromatography relies on reproducible 1st dimension separations. Aqueous separations such as IEX can involve preparing multiple sets of buffers over the course of a project. This iterative process is time consuming and has an increased potential for error in buffer preparation resulting in irreproducible separations.

Auto•Blend Plus Technology is an integrated software solution designed to increase productivity and reproducibility of chromatographic separations. Auto•Blend Plus incorporates a solvent management system using pure solutions and concentrated stocks (Figure 2). The end user is presented with an easy-to-use gradient table interface, where the gradient is expressed directly in terms of pH and ionic strength. The software then automatically calculates the percentage of acid and base required for the specified pH using the known pKa value of the chosen buffer system or a small empirical calibration table. Auto•Blend Plus allows for multiple buffer compositions to be tested from a single set of pure components and can be easily automated to increase productivity.

 

Figure 2. Auto•Blend Plus Technology. A) Auto•Blend Plus Technology automatically blends the desired gradients from concentrated stocks using pure solutions in combination with a quaternary solvent management system. B) The intuitive interface can be programmed to generate gradient conditions with either constant salt or pH.

Biotherapeutic characterization employing orthogonal techniques on-line with 2D UPLC-MS

Biotherapeutics undergo routine analysis throughout the manufacturing process to ensure regulatory guidelines are met with regards to product quality. Orthogonal techniques that can be employed to characterize the homogeneity (or lack thereof) in biotherapeutics drugs without compromising productivity are highly desirable.

The ACQUITY UPLC H-Class Bio System with 2D Technology is capable of combining complementary orthogonal detection techniques on-line for improved productivity. The heart-cut technology featured in the system is readily deployed with a two column configuration (IEX/RPLC) as shown in Figure 1 for on-line desalting of biotherapeutic samples, which was demonstrated in part I of this application series.

To demonstrate the MS amenability of this technology in comparability analyses, a Xevo G2 QTof Mass Spectrometer was interfaced with the 2D UPLC system after the ACQUITY UPLC Photodiode Array Detector as shown in Figure 1. Heart-cuts were performed on the individual lysine variants as outlined by the red box in Figure 3A–C. Using the same method and gradients as described in part 1, heart-cut fractions were desalted and eluted with the BSM pump to the source of the Xevo Mass Spectrometer (settings in MS conditions).

From the deconvoluted mass spectrums shown in Figure 3, the infliximab +0 Lys, +1 Lys, and +2 Lys peak mass were determined to be 148,511.0 Da, 148,640.0 Da, and 148,767.0 Da, respectively. The +1 Lys and +2 Lys peaks were determined to have a mass difference of Δ129 Da, and Δ256 Da, respectively, which correlates to the addition of one and two lysine residues (average mass 128 Da) while the glycosylation profile was confirmed to be identical between the major isoforms.

This application demonstrates that the ACQUITY UPLC H-Class Bio System with 2D Technology is well-suited for desalting of biological samples and renders a viable option to interface IEX with ESI-MS analysis as an orthogonal detection technique.

Figure 3. Lysine variant characterization using 2D UPLC-MS. Individual heart-cuts of the A) Lys +0, B) Lys +1, and C) Lys +2 were performed on the bio therapeutic infliximab. Heart-cut fractions were desalted on-line and eluted to a Xevo Mass Spectrometer. Deconvoluted mass are shown below the corresponding heart-cut.

Conclusion

Characterization methods of biotherapeutic proteins that provide increased informational content without compromising productivity require efficient solutions that are adaptable to the high-throughput environment of industry. The ACQUITY UPLC H-Class Bio System with 2D Technology offers an efficient method for the characterization of biotherapeutics with the ability to combine orthogonal detection techniques on-line for improved productivity.

The heart-cut feature offered with the system is well suited for fractionation and desalting of challenging biological samples. Compatibility with multiple column configurations and the ability to automate the process offers today’s analyst a flexible and efficient means to maximize the information obtained during characterization of biotherapeutics.

References

  1. Cheng et al. C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes. Biotechnology and Bioengineering. 2008; 100(6): 1132–1143.
  2. Brorson, K., Jia A. Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. Current Opinion in Biotechnology. 2014; 30: 140–146.
  3. Nechansky et al. Analysis of lysine clipping of a humanized lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. Journal of Chromatography B. 2007; 852(1–2): 250–256.
  4. Barnes, C., Lim, A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrometry Reviews. 2007; 26(3): 370–388.
  5. Annesley, T. Ion Suppression in Mass Spectrometry: Clinical Chemistry. 2003; 49(7): 1041–1044.

720005328, March 2015

Back To Top